CereVasc retweeted
🚨 Patients with Normal Pressure Hydrocephalus could now possibly benefit from a new device: the eShunt, through an endovascular minimally invasive procedure by enrolling in the STRIDE trial! @TJUHNeurosurg is the only site in Pennsylvania and today we did the first case in the tri-state area @TJUHospital @NeuroatJeff @JeffersonUniv
The STRIDE clinical trial is evaluating the safety and efficacy of the eShunt System®—a minimally invasive treatment for normal pressure hydrocephalus (NPH). During a recent webinar, Ricardo Hanel, MD, PhD, explained the procedure and how the device works.
Learn More: nphstridestudy.com/for-hcps.…
With 18 active sites and more coming soon, the STRIDE clinical trial is the largest study in the treatment of normal pressure hydrocephalus (NPH). It is evaluating the first endovascular treatment approach for people with NPH. Watch to find a nearby trial site.
1
2
230
CereVasc retweeted
Navin had trouble walking, remembering, and needed help with daily tasks—signs of normal pressure hydrocephalus (NPH), caused by fluid buildup in the brain.
A new study helped treat his condition without major surgery. Now he walks 3–4 miles a day! #URochesterResearch
CereVasc retweeted
🚨 Study Approved in Canada!
STRIDE trial is launching to study the eShunt System — an endovascular alternative to VP shunts for normal pressure hydrocephalus (NPH).
👥 Now enrolling potential candidates
📩 [email protected]
@RADIS_lab @SmhNeuroVasc @StMichaelsFdn
Your patients aged 60+ years with normal pressure hydrocephalus (NPH) may be right and ready for the STRIDE clinical trial—a study evaluating a new endovascular shunt. Watch to learn more about eligibility requirements.
nphstridestudy.com/for-hcps.…
The STRIDE clinical trial is evaluating the safety and efficacy of the investigational eShunt® System—an endovascular approach to normal pressure hydrocephalus (NPH) treatment. Ivan Lylyk, MD, and Pedro Lylyk, MD, explain the trial’s significance and how the eShunt System differs from a traditional shunt procedure.
Caution: The eShunt System is an investigational device and is not available for sale within or outside the US.
#NPH #Neurosurgeons #Neurologists #Neurosurgery #Neurology #Hydrocephalus #HydrocephalusAwareness
nphstridestudy.com/for-hcps.…
15
543
CereVasc retweeted
🚀 Breaking new ground in hydrocephalus treatment! 🌟 The eShunt System by CereVasc, featured in @JNIS_BMJ, offers an innovative endovascularly implantable cerebrospinal fluid shunt. Dive into the technical video for a step-by-step guide, key anatomic insights, and strategies to overcome common challenges. #MedicalInnovation #Neurosurgery #TechInMedicine 📽️👉 bit.ly/3FgWVcA
CereVasc retweeted
Billy Joel has NPH. It is an uncommon condition of the elderly causing 3Bs. Balance (gait dysfunction), Brain (memory problems), Bladder (urinary incontinence). Traditionally treated with VP shunt. There’s a new game in town. The e-shunt. @CereVasc Minimally invasive and innovative. The STRIDE trial is a randomized controlled trial comparing the new eShunt to traditional open surgery with VP shunt. Have more questions come to Montefiore-Einstein.
CereVasc retweeted
Doctors at @BaptistHealthJx may be on the vanguard of addressing normal pressure hydrocephalus, a condition that affects 800,000 older Americans.
A shunt system that's minimally invasive & promotes faster recovery, courtesy of @CereVasc: tinyurl.com/29h4frx9
@HydroAssoc
CereVasc retweeted
We all want hydrocephalus treatment that isn't brain surgery.
Diana Gray, CEO at HA speaks with Dr. @MatoukCharles from @Yale about the eShunt System - a minimally invasive treatment that could revolutionize how #hydrocephalus is managed.
📹 youtu.be/R7QYnoNMXXg
@CereVasc
CereVasc retweeted
📣 In Case You Missed It:
Dr. Ivan Lylyk joined us for GNI Grand Rounds to share his experience with the eShunt — a breakthrough in minimally invasive hydrocephalus treatment.
🧠 Explore how this innovation is reshaping CSF management and improving patient outcomes.
🎥 Now available to watch on YouTube
🔗 Watch via the link in our bio!
#neuro #neurosurgery #shunt #chiari #medical #health #neuroscience #brain #education #medstudent #fyp #trending #medicalnews
CereVasc retweeted
Happy to be a part of this trial and get to work with such a great team!!
We are excited to announce we received our second Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the eShunt System.
The Breakthrough Device Designation is for the treatment of communicating hydrocephalus in pediatric patients aged 12 and older, and was supported by data generated during our pilot clinical studies of the device, as well as original research published in the @JNIS_BMJ
“The recognition of Breakthrough Device Designation for the eShunt System in pediatric aged patients demonstrates the profound need for treatment innovation in this patient population and reinforces the potential safety and efficacy benefits that have already been observed with this minimally invasive, endovascular approach,” said Daniel Levangie
We look forward to continuing our collaboration with the FDA and our partners as we explore next steps in potentially shifting the standard of care for this critical patient population.
prnewswire.com/news-releases…
#NPH #hydrocephalus #eShunt
We are excited to announce we received our second Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the eShunt System.
The Breakthrough Device Designation is for the treatment of communicating hydrocephalus in pediatric patients aged 12 and older, and was supported by data generated during our pilot clinical studies of the device, as well as original research published in the @JNIS_BMJ
“The recognition of Breakthrough Device Designation for the eShunt System in pediatric aged patients demonstrates the profound need for treatment innovation in this patient population and reinforces the potential safety and efficacy benefits that have already been observed with this minimally invasive, endovascular approach,” said Daniel Levangie
We look forward to continuing our collaboration with the FDA and our partners as we explore next steps in potentially shifting the standard of care for this critical patient population.
prnewswire.com/news-releases…
#NPH #hydrocephalus #eShunt
CereVasc retweeted
.@CereVasc has reported initial results from its pilot @US_FDA-approved IDE clinical study of the eShunt system in the treatment of elderly patients with normal-pressure hydrocephalus
@CharlesMatouk @MatoukCharles
neuronewsinternational.com/c…
CereVasc retweeted
Team @Monte_NIS enrolled another patient in the @cerevasc pilot trial for the E-shunt, an endovascular treatment for NPH 🧠💦
🙏🏻🙏🏻🙏🏻 @circleowillis
@MontefioreRAD @MonteNeurosg @NeuroMonteEinst @MontefioreNYC – at Bronx, NY
Today we announced enrollment of the first patient in the STRIDE clinical trial of the eShunt® System for normal pressure hydrocephalus. Learn more about this unique study with clinical trial site locations in the United States and around the world.
prnewswire.com/news-releases…
Do your patients experience shuffling feet, cognitive impairment, or incontinence? These symptoms may be normal pressure #hydrocephalus and may prequalify your patients for the STRIDE #clinicaltrial—evaluating the #endovascular eShunt® system.
Learn more: STRIDEclinicaltrial.com
Minimally Invasive Procedure Making Treatment Possible for More People with Normal Pressure Hydrocephalus | By Dan Levangie, President and CEO of CereVasc infomeddnews.com/dan-levangi… via @MedDeviceNews1
1
359
We're thrilled to announce that @CereVasc has been recognized by @NewEnglandVC as a nominee for the Emerging MedTech Company of the Year at the 12th Annual #NEVYs24!
We look forward to joining our fellow innovators and celebrating #NEVYsSurvivor at the House of Blues on Dec 5th.